Trial reportKorean journal of ophthalmology : KJO2009
Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm.
Trial report in Korean journal of ophthalmology : KJO, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01180348 (Randomized Study of Clinical Non-inferiority of Medicine Botulift), which is not on this map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Study of Clinical Non-inferiority of Medicine Botulift (Laboratório Químico Farmacêutico Bergamo Ltd.) Compared to Botox ® (Allergan Inc.) in the Improvement of Wrinkles in the Facial Region.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Comparative efficacy and safety of botulinum neurotoxin type A in blepharospasm and hemifacial spasm: a systematic review and Bayesian network meta-analysis.Journal of neural transmission (Vienna, Austria : 1996) · 2026Pooled it
- Effectiveness of Botulinum Toxin Injection on Bruxism: A Systematic Review and Meta-analysis of Randomized Controlled Trials.Aesthetic plastic surgery · 2023Pooled it
- Comparison of Safety and Efficacy of Botox and Neuronox in the Management of Benign Essential Blepharospasm: A Split-face Study.Korean journal of ophthalmology : KJO · 2019Trial
- The efficacy and safety of neubotulinumtoxinA for the treatment of forehead horizontal lines in Asians - A clinical, prospective, interventional, split-face study.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
- Article
- [New botulinum toxins for aesthetic dermatology : A comprehensive review].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2021Review
- FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia.Toxins · 2020Review
- Increased pupillary constriction velocity in benign essential blepharospasm associated with photophobia.PloS one · 2019Article
- Long-term Efficacy of Botulinum Neurotoxin-A Treatment for Essential Blepharospasm.Korean journal of ophthalmology : KJO · 2018Article
- Impact of Neu-botulinumtoxinA on the Severity and Quality of Life of Cervical Dystonia Patients.Tremor and other hyperkinetic movements (New York, N.Y.) · 2016Article
- Botulinum toxin for the treatment of movement disorders.Current neurology and neuroscience reports · 2012Review
- Botulinum toxin injections for blepharospasm prior to ocular surgeries.Clinical ophthalmology (Auckland, N.Z.) · 2012Article
- Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm.Journal of neural transmission (Vienna, Austria : 1996) · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the efficacies and safeties of Meditoxin (Medy-Tox, Korea) and Botox in the treatment of essential blepharospasm.
methodsWe performed a double-blind, randomized, comparative trial comparing Meditoxin and Botox for treatment of blepharospasm in 60 patients from the intention-to-treat (ITT) population and 52 patients from the per-protocol (PP) population. We analyzed the improvements in severity of spasm (SS) at four weeks post-injection as a primary efficacy outcome. Changes in eyelid closing force (CF) and functional visual status (FVS) after injection were analyzed for secondary efficacy outcomes, and adverse effects were demonstrated for the safety evaluation.
resultsImprovement in SS was noted in 90.3% of the Meditoxin group and 86.2% of the Botox group. There were no significant differences between treatment groups in the changes of CF and FVS post-injection (p>0.05). Since the lower limit of the 95% confidence interval (-1.76% for ITT, -1.64% for PP) was over the -15% threshold, we determined that Meditoxin was not inferior to Botox in either the ITT or PP populations. Adverse effects developed in 16.1% of the Meditoxin group and 27.6% of the Botox group, but no serious adverse events were found in either group.
conclusionsMeditoxin and Botox were comparable in efficacy and safety in the treatment of essential blepharospasm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.